Treatment of Relapsed/Refractory Non Hodgkin Lymphoma Patients with Venetoclax Therapy: A Single-Center Evaluation of off-label use

ConclusionVenetoclax therapy in a real-world cohort offered modest benefits in heavily-pretreated patients. Adverse events were observed at higher incidence compared to clinical trials. A wide heterogeneity of venetoclax dose escalation, multi-agent combinations, and timing of initiation were identified and would best be investigated in subsequent clinical trials.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

Conditions:   Lung Transplant Failure and Rejection;   Primary Graft Dysfunction Intervention:   Other: blood and exhaled breath specimens Sponsor:   University Hospital, Antwerp Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Chronic Pain;   Liver Transplantation Intervention:   Drug: FK506 Sponsors:   The Second Hospital of Tangshan;   Chinese PLA General Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Multiple Myeloma Interventions:   Drug: CellProtect;   Drug: Isatuximab Sponsors:   Karolinska Institutet;   Sanofi Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Multiple Myeloma Intervention:   Drug: autologous NK cells Sponsor:   Karolinska University Hospital Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Guillen-Climent S, García-Vázquez A, Martínez-Ciarpaglini C PMID: 32951879 [PubMed - as supplied by publisher]
Source: Medicina Clinica - Category: General Medicine Tags: Med Clin (Barc) Source Type: research
CONCLUSION: sAPRIL, a simple, promising blood test, which can be measured by ELISA, will seemingly attain a place in the wide range of prognostic markers in CLL. Prospective large-scale studies are required to validate and confirm the feasibility of the proposed cut-off level of 2.04 ng/ml as a predictor of time to treatment in treatment naive CLL patients. PMID: 32950049 [PubMed - as supplied by publisher]
Source: Turkish Journal of Medical Sciences - Category: General Medicine Tags: Turk J Med Sci Source Type: research
CONCLUSIONS: SRFA is an effective minimal-invasive treatment option in pediatric patients with liver tumors of different etiologies. PMID: 32954876 [PubMed - in process]
Source: International Journal of Hyperthermia - Category: Internal Medicine Tags: Int J Hyperthermia Source Type: research
Conclusions: In BA infants, it is possible to determine CT-based body metrics during LT screening with very strong interobserver agreement. Poor correlation between CT-based body metrics and MUAC suggests that CT-based body metrics provide additional information on body composition in BA infants, such as relative muscle mass.
Source: Journal of Pediatric Gastroenterology and Nutrition - Category: Gastroenterology Tags: Original Articles: Hepatology Source Type: research
Conclusions: AT after KP confirmed conflicting results; therefore, multicentered, prospective, randomized control studies are needed to better understand its utility after KP, especially in the multidrug resistance spread era.
Source: Journal of Pediatric Gastroenterology and Nutrition - Category: Gastroenterology Tags: Original Articles: Hepatology Source Type: research
ConclusionVenetoclax therapy in a real-world cohort offered modest benefits in heavily pretreated patients. Adverse events were observed at a greater incidence than in the clinical trials. A wide heterogeneity of venetoclax dose escalation, multiagent combinations, and timing of initiation were identified and require investigation in subsequent clinical trials.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Clinical Trials | Hodgkin's Disease | Leukemia | Lymphoma | Myeloma | Non-Hodgkin's Lymphoma | Study | Thrombocytopenia | Transplants